pharmaphorum

APRIL 20, 2021

According to Novartis, Kesimpta is the first targeted B cell therapy for RMS that can be self-administered at home once a month using an autoinjector, avoiding the need for patients to travel to hospital during the pandemic, and easing the pressure on clinicians. GlobalData thinks Ocrevus will remain the most widely-used option, hitting $7.6

Sales 109

Sales Medicine Drugs Marketing 109

The Pharma Data

DECEMBER 3, 2020

Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. The trimeric S protein of SARS-CoV-2 is responsible for binding to host cell surface receptor ACE2 and subsequent viral entry, making it the primary target antigen for vaccine development.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

JANUARY 28, 2022

Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose. It targets gp100, which is a glycoprotein expressed in melanocytes and a tumor-associated antigen in melanoma. The median treatment time is about 23 weeks (or 5.3 months), so the average cost per patient will be approximately $400,000.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

The Pharma Data

JANUARY 31, 2021

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. The trimeric S protein of SARS-CoV-2 is responsible for binding to host cell surface receptor ACE2 and subsequent viral entry, making it the primary target antigen for vaccine development.

Vaccination 52

Vaccination Vaccine Trials Protein 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells. Treatment vaccines : these boost the immune system responses to target cells.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

OCTOBER 9, 2021

This designation is predicated on data showing that gantenerumab significantly reduced brain amyloid pillar, a pathological hallmark of Notice, in the ongoing SCarlet RoAD and Marguerite RoAD open- tag extension trials, as well as other studies.

Antibody 52

Antibody In-Vitro Trials Development 52

Delveinsight

FEBRUARY 25, 2021

The gene-editing technologies, which have reached the clinic, CRISPR, zinc finger nucleases, and TALENs, make their edits by nicking DNA at the target site. Combining immuno-oncology treatments such as checkpoint inhibitors with other cancer-killing drugs is considered a remarkable strategy for enhancing the response rate to immunotherapy.

DNA 52

DNA In-Vivo Genetics Medicine 52

Drug Discovery World

NOVEMBER 13, 2023

On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against membrane protein targets, engineering bispecific antibodies, next-generation immunotherapies, protein stability and formulation, and protein process development.

Protein 59

Protein Antibody Engineer Scientist 59

XTalks

JANUARY 19, 2024

These include isotopes like iodine-131 for treating thyroid cancer or yttrium-90 for targeted radiotherapy in certain cancers. To specifically target cancer cells, alpha-emitting radionuclides are often attached to molecules that have a high affinity for cancer cells, such as antibodies or peptides (ligands).

DNA 66

DNA Radiology FDA Approval Development 66

Drug Discovery World

NOVEMBER 9, 2023

Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’. These include: Chairperson Keyt on: ‘IgM antibodies as receptor cross-linking agents for DR-5 and other TNF targets’. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

NOVEMBER 15, 2020

Peng Liang , Founder and Chief Scientific Officer of Clover and inventor of the Trimer-Tag© technology, says, “A successful vaccine that can truly modulate the course of the COVID-19 pandemic must have four essential characteristics: safety, efficacy, scalability of manufacturing, and speed.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52

XTalks

DECEMBER 21, 2022

The multi-million-dollar price tags are largely attributable to the high R&D and manufacturing costs associated with making a gene therapy, as the raw materials for producing the therapy can be expensive. The majority of gene therapies approved and under development are in the areas of oncology and rare disease.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

Delveinsight

DECEMBER 3, 2020

Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. Roche receives FDA authorization for the quantitative COVID-19 antibody test. Merck chooses TriNKET cancer immunotherapy program.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Rethinking Clinical Trials

JUNE 14, 2023

When evaluating when and how RWE studies complement RCTs, it’s important to consider the target trial design that would best match the need or questions of the end users. We’ve also launched a spin-off project called ENCORE which is focused on emulating oncology trials using oncology specialty EHR data.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130

The Pharma Data

MAY 4, 2021

Biosimilars, which grew 79% operationally to $530 million, primarily driven by recent oncology monoclonal antibody biosimilar launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab) globally, as well as continued growth from Retacrit (epoetin) in the U.S.; Adjusted Diluted EPS (2). 47%. . . . . 1,611. . *. *.

Vaccination 40

Vaccination Vaccine Production Sales 40